(Q45628504)

14 December 2017

An ELISA for putative neutralizing antibodies to hepatitis E virus detects antibodies to genotypes 1, 2, 3, and 4. (English)

1 reference

14 December 2017

1 reference

1 reference

hepatitis E virus

1 reference

3

Suzanne U Emerson

1 reference

14 December 2017

2

Robert H Purcell

1 reference

14 December 2017

Yi-Hua Zhou

1

1 reference

PubMed ID

15193383

14 December 2017

language of work or name

English

0 references

publication date

1 June 2004

1 reference

14 December 2017

8

1 reference

based on heuristic

inferred from page(s)

published in

Vaccine

1 reference

14 December 2017

22

1 reference

14 December 2017

20

1 reference

14 December 2017

2578-2585

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.017

14 December 2017

1 reference

Role of hepatitis E and other hepatotropic virus in aetiology of sporadic acute viral hepatitis: a hospital based study from urban Delhi

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.017

Novel hepatitis E virus (HEV) isolates from Europe: evidence for additional genotypes of HEV.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.017

Full-genome nucleotide sequence of a hepatitis E virus strain that may be indigenous to Japan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.017

The sequence and phylogenetic analysis of a novel hepatitis E virus isolated from a patient with acute hepatitis reported in the United States

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.017

Aetiology, clinical course and outcome of sporadic acute viral hepatitis in pregnancy*

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.017

Viral hepatitis during pregnancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.017

Hepatitis E virus superinfection in patients with chronic liver disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.017

Fulminant Hepatitis E in Japan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.017

Genetic heterogeneity of hepatitis E virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.017

The ORF3 protein of hepatitis E virus binds to Src homology 3 domains and activates MAPK.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.017

Structural characterization of recombinant hepatitis E virus ORF2 proteins in baculovirus-infected insect cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.017

Epidemic hepatitis E in Pakistan: patterns of serologic response and evidence that antibody to hepatitis E virus protects against disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.017

Successful passive and active immunization of cynomolgus monkeys against hepatitis E

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.017

Long-term serological follow up and cross-challenge studies in rhesus monkeys experimentally infected with hepatitis E virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.017

Recombinant vaccine against hepatitis E: dose response and protection against heterologous challenge.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.017

A bacterially expressed peptide prevents experimental infection of primates by the hepatitis E virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.017

Recombinant vaccine against hepatitis E: duration of protective immunity in rhesus macaques.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.017

Pre-clinical immunogenicity and efficacy trial of a recombinant hepatitis E vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.017

Immunodominant antigenic regions in a structural protein of the hepatitis E virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.017

Recombinant subunit ORF2.1 antigen and induction of antibody against immunodominant epitopes in the hepatitis E virus capsid protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.017

Identification of immunodominant and conformational epitopes in the capsid protein of hepatitis E virus by using monoclonal antibodies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.017

Identification and characterization of the neutralization epitope(s) of the hepatitis E virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.017

Identification by phage display and characterization of two neutralizing chimpanzee monoclonal antibodies to the hepatitis E virus capsid protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.017

Monoclonal antibodies that neutralize HEV recognize an antigenic site at the carboxyterminus of an ORF2 protein vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.017

Evaluation of assays for antibody to hepatitis E virus by a serum panel. Hepatitis E Virus Antibody Serum Panel Evaluation Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.017

ELISA for IgG-class antibody to hepatitis E virus based on a highly conserved, conformational epitope expressed in Escherichia coli

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.017

Empty virus-like particle-based enzyme-linked immunosorbent assay for antibodies to hepatitis E virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.017

A new enzyme immunoassay for the detection of antibody to hepatitis E virus.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.017

Hepatitis E virus (HEV) capsid antigens derived from viruses of human and swine origin are equally efficient for detecting anti-HEV by enzyme immunoassay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.017

Characterization of a prototype strain of hepatitis E virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.017

ELISA for antibody to hepatitis E virus (HEV) based on complete open-reading frame-2 protein expressed in insect cells: identification of HEV infection in primates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.017

Construction of T-vectors, a rapid and general system for direct cloning of unmodified PCR products

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.12.017

10.1016/J.VACCINE.2003.12.017

7 January 2021

Identifiers

DOI

1 reference

14 December 2017

1 reference

PubMed ID

15193383